Search

Daratumumab, a CD38 monoclonal antibody study in advanced multiple myeloma – an open-label, dose escalation followed by open-label extension in a single-arm phase I/II study

Daratumumab is a human CD38 monoclonal antibody being tested against multiple myeloma, but it could also have potential in a broad range of other hematological diseases.

Read more

EHA-SPSHTM joint membership

Save money and time by becoming a joint member of EHA and the Scientific and Practical Society of Hematologists and Transfusiologists from the Republic of Moldova.

Read more

EHA reaffirms commitment to hematology's future with new brand identity

The European Hematology Association (EHA) is thrilled to announce the launch of our new brand identity. This includes a refreshed logo, updated color palette, and a new slogan, marking a significant milestone in our journey.

Read more

What an EHA Innovation Grant supports

Our EHA Innovation Grant supports high-quality clinical or translational research in hematology. To reflect the collaborative spirit of the grant, no more than 40% of the total grant should be allocated to one member of the consortium.

Read more

Grants & abstract awards

EHA Travel GrantsThe call for travel grant applications closed on March 1, 2025 (23:59 CET). The grants will only be available for investigators with accepted abstracts, submitted during the regular abstract submission.

Read more